Late Breaking clinical trial #HOPE-3 OLE shows striking benefits of #deramiocel sustained over two years of therapy, and 76% slowing of #Duchenne myopathy progression in those who crossed over from placebo to deramiocel after one year. Work of ace #DMD trialist Craig McDonald highlighted at the @WorldMuscleSoc meeting in Hiroshima. Trial sponsored by @Capricor based on intellectual property from my team at Cedars-Sinai.
Capricor is headed to the 2026 World Muscle Society Congress in Hiroshima, Japan, September 29 – October 3.
We’re looking forward to sharing new HOPE-3 open-label extension data for Deramiocel in Duchenne muscular dystrophy, including skeletal muscle and cardiac outcomes through 24 months. Dr. Craig McDonald of UC Davis will present the findings in a late-breaking poster and an oral presentation, alongside additional research from our StealthX™ platform exploring muscle-targeting extracellular vesicle technologies.
We’re proud to continue advancing the science and working toward better options for boys and families living with Duchenne. 💙
Read more: https://t.co/Pwcnry8Z3u
$CAPR #Deramiocel #Duchenne #DMD #exosomes #WMS2026 #WorldMuscleSociety
Bloodstream-delivered cell therapy slows muscle decline in young people with Duchenne muscular dystrophy, phase 3 trial finds.
Explore the research 👉 https://t.co/cCXDL550TO